THE BEST SIDE OF HEMGENIX

Amount of eligible patients: CDEC discussed the uncertainty in the volume of clients with moderately extreme to extreme hemophilia B in Canada suitable for etranacogene dezaparvovec. Scientific authorities consulted by CADTH indicated that some people that are classified as acquiring gentle or average illness could have a serious bleeding phenotype